Rein Therapeutics (015A) Stock Statistics & Valuation Metrics
Total Valuation
Rein Therapeutics has a market cap or net worth of EUR 51.75M. The enterprise value is EUR 74.13M.
- Market Cap
- EUR 51.75M
- Enterprise Value
- EUR 74.13M
Share Statistics
Rein Therapeutics has 86,267,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 86,267,030
- Owned by Insiders
- 1.76%
- Owned by Institutions
- 9.20%
Financial Efficiency
Rein Therapeutics’s return on equity (ROE) is -2.95 and return on invested capital (ROIC) is -120.27%.
- Return on Equity (ROE)
- -2.95
- Return on Assets (ROA)
- -2.06
- Return on Invested Capital (ROIC)
- -120.27%
- Return on Capital Employed (ROCE)
- -1.22
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.99M
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Rein Therapeutics is -0.35. Rein Therapeutics’s PEG ratio is -0.01.
- PE Ratio
- -0.35
- PS Ratio
- 0.00
- PB Ratio
- 1.89
- Price to FCF
- -2.91
- Price to Operating Cash Flow
- -1.02
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Rein Therapeutics had revenue of 0 and earned -49.87M in profits. Earnings per share was -1.96.
- Revenue
- 0
- Gross Profit
- -1,000
- Operating Income
- -21.93M
- Pretax Income
- -50.58M
- Net Income
- -49.87M
- EBITDA
- -50.58M
- Earnings Per Share (EPS)
- -1.96
Cash Flow
In the last 12 months, operating cash flow was -18.83M and capital expenditures 0, giving a free cash flow of -18.83M billion.
- Operating Cash Flow
- -18.83M
- Free Cash Flow
- -18.83M
- Free Cash Flow per Share
- -0.62
Dividends & Yields
Rein Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -33.57%
- Earnings Yield
- -252.09%
Stock Price Statistics
- Beta
- ―
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 3.14
- 200-Day Moving Average
- 3.14
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Rein Therapeutics upcoming earnings date is Nov 06, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 06, 2026
- Ex-Dividend Date
- ―
Financial Position
Rein Therapeutics as a current ratio of 0.70, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.70
- Quick Ratio
- 0.70
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.06
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Rein Therapeutics has paid -712.00K in taxes.
- Income Tax
- -712.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Rein Therapeutics EV to EBITDA ratio is -2.26, with an EV/FCF ratio of -2.53.
- EV to Sales
- 0.00
- EV to EBITDA
- -2.26
- EV to Free Cash Flow
- -2.53
- EV to Operating Cash Flow
- -2.53
Balance Sheet
Rein Therapeutics has EUR 40.65M in cash and marketable securities with EUR 0.00 in debt, giving a net cash position of EUR 40.65M billion.
- Cash & Marketable Securities
- EUR 40.65M
- Total Debt
- EUR 0.00
- Net Cash
- EUR 40.65M
- Net Cash Per Share
- EUR 0.47
- Tangible Book Value Per Share
- -EUR 0.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Rein Therapeutics is EUR 5.37, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 5.37
- Price Target Upside
- 70.93% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 3
- AI Score
- ―
